The fully automated serology test to detect IgG antibodies
The new LIAISON® SARS-CoV-2 S1/S2 IgG test provides diagnostic laboratories with:
- A fully automated quantitative solution for the detection of IgG antibodies against S1/S2 antigens of SARS-CoV-2
- Up to 170 results/hour on LIAISON® XL
- High sensitivity (97.4%) and specificity (98.5%) to assure accurate results
- Detection of Neutralizing antibodies: 94.4% positive agreement to Plaque Reduction Neutralization Test (PRNT)
The LIAISON® SARS-CoV-2 IgG assay complements DiaSorin’s family of over 50 specialty Infectious Disease tests, which includes the first automated TORCH panel on the market, QuantiFERON® for latent tuberculosis & Procalcitonin for sepsis.
Discover DiaSorin’s Infectious Disease product family
SARS-CoV-2 and CoVID-19: Background
Coronavirus disease (COVID-19) is a respiratory infectious disease caused by the newly discovered coronavirus SARS-CoV-2. The first cases were reported by Chinese authorities in December 2019, in Wuhan City, Hubei province. The initial outbreak in Wuhan spread rapidly, affecting first other regions of China and then an increasing number of countries world- wide. The Director General of the World Health Organization declared COVID-19 a global pandemic on 11 March 2020. (1)
Intended use of the test
The LIAISON® SARS-CoV-2 S1/S2 IgG uses chemiluminescence immunoassay (CLIA) technology for the quantitative determination of anti-S1 and anti-S2 specific IgG antibodies to SARS-CoV-2 in human serum or plasma samples. The assay is intended as an aid in the diagnosis of CoVID-19 and to support the study of the immune status of infected patient by providing an indication of presence of neutralizing IgG antibodies against SARS-CoV-2. However, the result of the test alone cannot be used to exclude that the patient is still infectious.
The test has to be performed on the LIAISON® XL Analyzer only.
|LIAISON® SARS-CoV-2 S1/S2 IgG test||311450|
|LIAISON® SARS-CoV-2 S1/S2 IgG controls||311451|
(1) European Centre for Disease Prevention and Control (ECDC). Novel Coronavirus.
Available from: https://www.ecdc.europa.eu/en/novel-coronavirus-china